180 related articles for article (PubMed ID: 31793719)
1. Aberrant expression of ADAM9 in ovarian cancer and its clinical significance.
Guo T; Yuan D; Lin M; Zhu D; Xu N; Wang J
J Clin Lab Anal; 2020 Apr; 34(4):e23136. PubMed ID: 31793719
[TBL] [Abstract][Full Text] [Related]
2. ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas.
Fan X; Wang Y; Zhang C; Liu L; Yang S; Wang Y; Liu X; Qian Z; Fang S; Qiao H; Jiang T
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27571068
[TBL] [Abstract][Full Text] [Related]
3. Circ_0005276 aggravates the development of epithelial ovarian cancer by targeting ADAM9.
Liu ZH; Liu WJ; Yu XY; Qi XL; Sun CC
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10375-10382. PubMed ID: 33155193
[TBL] [Abstract][Full Text] [Related]
4. ADAM9 Expression in Uterine Cervical Cancer and Its Associated Factors.
Mohd Isa SA; Md Salleh MS; Ismail MP; Hairon SM
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1081-1087. PubMed ID: 31030477
[TBL] [Abstract][Full Text] [Related]
5. Cancer-testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis.
Lin L; Nong W; Luo B; Ge Y; Zeng X; Li F; Fan R; Zhang Q; Xie X
Immun Inflamm Dis; 2021 Dec; 9(4):1759-1770. PubMed ID: 34528758
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of up-regulated lncRNA NEAT1 in prognosis of ovarian cancer.
Chen ZJ; Zhang Z; Xie BB; Zhang HY
Eur Rev Med Pharmacol Sci; 2016 Aug; 20(16):3373-7. PubMed ID: 27608895
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of ALDH5A1 predicts prognosis in patients with ovarian cancer.
Tian X; Han Y; Yu L; Luo B; Hu Z; Li X; Yang Z; Wang X; Huang W; Wang H; Zhang Q; Ma D
Cancer Biol Ther; 2017 Apr; 18(4):245-251. PubMed ID: 28346042
[TBL] [Abstract][Full Text] [Related]
9. Relevance of A Disintegrin and Metalloproteinase Domain-Containing (ADAM)9 Protein Expression to Bladder Cancer Malignancy.
Moriwaki M; Le TT; Sung SY; Jotatsu Y; Yang Y; Hirata Y; Ishii A; Chiang YT; Chen KC; Shigemura K; Fujisawa M
Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740916
[TBL] [Abstract][Full Text] [Related]
10. ADAM9 decreases in castration resistant prostate cancer and is a prognostic factor for overall survival.
Lin GW; Yao XD; Ye DW; Zhang SL; Dai B; Zhang HL; Ma CG
Chin Med J (Engl); 2012 Nov; 125(21):3800-5. PubMed ID: 23106877
[TBL] [Abstract][Full Text] [Related]
11. Leptin Protein Expression and Promoter Methylation in Ovarian Cancer: A Strong Prognostic Value with Theranostic Promises.
Assidi M; Yahya FM; Al-Zahrani MH; Elkhatib R; Zari A; Elaimi A; Al-Maghrabi J; Dallol A; Buhmeida A; Abu-Elmagd M
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884678
[TBL] [Abstract][Full Text] [Related]
12. An integrated model of CDCA5 and FOXM1 expression combined with a residual disease that predicts prognosis in ovarian cancer patients.
Zhang Q; Zhang R; Liu M; Wu H; Yang B
Cell Mol Biol (Noisy-le-grand); 2023 Oct; 69(10):143-149. PubMed ID: 37953569
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA‑302a suppresses cell proliferation, migration and invasion in osteosarcoma by targeting ADAM9.
Yang X; Cui Y; Yang F; Sun C; Gao X
Mol Med Rep; 2017 Sep; 16(3):3565-3572. PubMed ID: 28713950
[TBL] [Abstract][Full Text] [Related]
14. [Relationships between decreased LAMC3 and poor prognosis in ovarian cancer].
Lei SM; Liu X; Xia LP; Ke Y; Wei LW; Li L; Yin FJ
Zhonghua Fu Chan Ke Za Zhi; 2021 Jul; 56(7):489-497. PubMed ID: 34304441
[No Abstract] [Full Text] [Related]
15. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK
Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
[TBL] [Abstract][Full Text] [Related]
16. Downregulated Long Noncoding RNA DGCR5 Acts as a New Promising Biomarker for the Diagnosis and Prognosis of Ovarian Cancer.
Chen H; Tian X; Luan Y; Lu H
Technol Cancer Res Treat; 2019; 18():1533033819896809. PubMed ID: 31868103
[TBL] [Abstract][Full Text] [Related]
17. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression.
Fritzsche FR; Wassermann K; Jung M; Tölle A; Kristiansen I; Lein M; Johannsen M; Dietel M; Jung K; Kristiansen G
BMC Cancer; 2008 Jun; 8():179. PubMed ID: 18582378
[TBL] [Abstract][Full Text] [Related]
18. A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients.
Heimes AS; Schmidt M; Jäkel J; Almstedt K; Gebhard S; Weyer-Eiberich V; Elger T; Krajnak S; Brenner W; Hasenburg A; Battista MJ
Arch Gynecol Obstet; 2019 Jan; 299(1):239-246. PubMed ID: 30357498
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer.
Ma RQ; Tang ZJ; Ye X; Cheng HY; Sun KK; Chang XH; Cui H
Arch Gynecol Obstet; 2018 May; 297(5):1235-1244. PubMed ID: 29428978
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in Ovarian Cancer Patients: Evidence from 52 Studies.
Tao Y; Li H; Huang R; Mo D; Zeng T; Fang M; Li M
Cell Physiol Biochem; 2018; 46(4):1716-1726. PubMed ID: 29730663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
